Bank of America Corp DE Takes $605.40 Million Position in Edwards Lifesciences Corporation $EW

Key Points

• Bank of America acquired 6.69 million Edwards Lifesciences shares worth approximately $605.4 million, giving it a 1.16% stake. Institutional investors and hedge funds collectively own 79.46% of the company.
• Analysts remain broadly positive, with 17 Buy ratings and six Holds; the stock has an overall “Moderate Buy” rating and an average price target of $100.27.
• Edwards Lifesciences exceeded quarterly expectations, reporting $0.78 in EPS versus a $0.74 estimate and $1.74 billion in revenue, up 13.6% year over year. Shares opened at $85.71, while recent insider activity reflected sales of company stock.

Bank of America Corp DE acquired a new stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 6,692,424 shares of the medical research company's stock, valued at approximately $605,397,000. Bank of America Corp DE owned 1.16% of Edwards Lifesciences at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Rehmann Capital Advisory Group raised its position in shares of Edwards Lifesciences by 2.1% during the 4th quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company's stock valued at $546,000 after buying an additional 130 shares during the period. Stephens Inc. AR increased its stake in Edwards Lifesciences by 5.4% during the fourth quarter. Stephens Inc. AR now owns 2,799 shares of the medical research company's stock worth $239,000 after acquiring an additional 144 shares during the last quarter. Aspen Investment Management Inc increased its stake in Edwards Lifesciences by 1.5% during the fourth quarter. Aspen Investment Management Inc now owns 10,381 shares of the medical research company's stock worth $885,000 after acquiring an additional 150 shares during the last quarter. Covestor Ltd raised its position in Edwards Lifesciences by 9.6% in the fourth quarter. Covestor Ltd now owns 1,784 shares of the medical research company's stock valued at $152,000 after purchasing an additional 157 shares during the period. Finally, Premier Path Wealth Partners LLC raised its position in Edwards Lifesciences by 4.4% in the first quarter. Premier Path Wealth Partners LLC now owns 3,880 shares of the medical research company's stock valued at $311,000 after purchasing an additional 162 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Leerink Partners upgraded Edwards Lifesciences from a "market perform" rating to an "outperform" rating and increased their price target for the stock from $87.00 to $101.00 in a report on Friday, July 24th. TD Cowen restated a "buy" rating on shares of Edwards Lifesciences in a report on Tuesday, July 21st. Royal Bank Of Canada upped their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company an "outperform" rating in a research report on Monday, July 13th. Piper Sandler reaffirmed an "overweight" rating and set a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. Finally, Wall Street Zen upgraded shares of Edwards Lifesciences from a "hold" rating to a "buy" rating in a research report on Saturday. Seventeen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $100.27.

Edwards Lifesciences Stock Up 0.2%

Shares of NYSE EW opened at $85.71 on Wednesday. The stock has a market cap of $49.35 billion, a P/E ratio of 49.26, a PEG ratio of 2.24 and a beta of 0.85. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $96.29. The business's fifty day simple moving average is $88.79 and its 200-day simple moving average is $85.85.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.74 by $0.04. The firm had revenue of $1.74 billion during the quarter, compared to analysts' expectations of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.Edwards Lifesciences's revenue for the quarter was up 13.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 619 shares of the stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $87.51, for a total value of $54,168.69. Following the transaction, the vice president owned 40,034 shares in the company, valued at approximately $3,503,375.34. This represents a 1.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Annette Brüls sold 2,644 shares of the firm's stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $89.98, for a total transaction of $237,907.12. Following the sale, the vice president directly owned 17,984 shares in the company, valued at approximately $1,618,200.32. The trade was a 12.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 5,664 shares of company stock valued at $511,918 over the last 90 days. 0.31% of the stock is owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation NYSE: EW is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.

The company's portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.